Molecular Analysis for Combination Therapy Choice

EAY-191
ComboMATCH Registration Trial
PI: James Ford

Genomic Data Reviewed and Treatment Trials Assignment Provided to Site

Other Arms to Open in the Near Future

Treatment trials

Previous Taxane Therapy

AKT Mutation

ECOG-ACRIN-EAY191-S3
Phase II Paclitaxel + Ipatasertib in Taxane-Refractory Participants w/ AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)
PI: Ford Sponsor: ECOG-ACRIN

No Mutations

ECOG-ACRIN-EAY191-E4
Nilotinib & Paclitaxel in Patients w/ Prior Taxane-Treated Solid Tumors (A ComboMATCH Treatment Trial)
PI: Ford Sponsor: ECOG-ACRIN

KEY
Pending
Open for Enrollment
Observational Study
Optimal Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu